Fluor (FLR) Form 144: 55,178 Shares Proposed Sale, $3.44M

Fluor Corporation filed a Form 144 notifying a proposed Rule 144 sale of 55,178 common shares through Merrill Lynch (Dallas) with an aggregate market value of $3,440,858.

Rhea-AI Filing Summary

Fluor Corporation filed a Form 144 notifying a proposed Rule 144 sale of 55,178 common shares through Merrill Lynch (Dallas) with an aggregate market value of $3,440,858. The shares are listed on the NYSE and the filing shows an approximate sale date of 08/11/2025. The proposed sale represents roughly 0.034% of Fluor's 161,664,371 outstanding shares.

The filing lists the securities as originally acquired as restricted stock equity awards from Fluor on 02/23/2016 (5,178 shares) and 11/11/2022 (46,785 shares). It also states no securities were sold in the past three months and includes the seller's representation that they do not possess undisclosed material adverse information; no trading-plan adoption date is indicated on the form.

Positive

• Specified share count and value: 55,178 shares totaling $3,440,858, providing clear disclosure of the proposed sale size.
• No recent sales: Filing states "Nothing to Report" for securities sold during the past three months.
• Acquisition transparency: All reported shares were acquired as restricted stock equity awards with acquisition dates and amounts listed.

Negative

• No 10b5-1 plan date indicated: The form does not show a trading-plan adoption date or instruction date, leaving execution method unspecified.
• Proposed sale date present: An approximate sale date of 08/11/2025 is given, which may introduce timing uncertainty for investors tracking insider activity.

Insights

Securities Analyst

TL;DR: A routine insider sale notice for 55,178 shares (~0.034% of float), modest in scale and unlikely to move the market materially.

The Form 144 reports a proposed sale of 55,178 common shares through Merrill Lynch with an aggregate market value of $3.44M, scheduled approximately for 08/11/2025. Relative to the reported outstanding share count of 161,664,371, the package is very small (~0.034%), indicating limited dilution or supply pressure from this single filing. The securities were acquired as restricted stock awards in 2016 and 2022, and the filer reports no sales in the past three months, which reduces immediate execution uncertainty. The absence of a stated 10b5-1 plan adoption date on the form leaves the execution framework unspecified in the filing itself.

Corporate Governance Expert

TL;DR: Disclosure follows Rule 144 format and includes required seller representations, but the filing does not specify a 10b5-1 plan date.

The document contains the standard representation that the seller does not possess undisclosed material adverse information and records the acquisition of shares via restricted equity awards (dates and amounts provided). It notes "Nothing to Report" for sales in the prior three months, which is consistent with a non-active seller. Material governance items are routine: the broker is identified and the exchange is NYSE. However, the form does not indicate a plan adoption or instruction date for any Rule 10b5-1 trading arrangement, which would otherwise provide stronger evidence of pre-planned disposal timing.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Fluor (FLR) report in this Form 144 filing?

The filing notifies a proposed Rule 144 sale of 55,178 common shares through Merrill Lynch with an aggregate market value of $3,440,858.

When is the proposed sale scheduled for FLR shares?

The filing lists an approximate sale date of 08/11/2025.

How large is the proposed sale relative to Fluor's outstanding shares?

The 55,178 shares represent about 0.034% of the 161,664,371 outstanding shares reported in the filing.

How were the shares being sold originally acquired?

The shares were acquired as restricted stock equity awards from Fluor on 02/23/2016 (5,178 shares) and 11/11/2022 (46,785 shares).

Has the seller reported recent sales of Fluor securities?

No; the filing states "Nothing to Report" for securities sold during the past three months.

Does the filing indicate a 10b5-1 trading plan date for the sale?

No specific plan adoption or instruction date is provided in the filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/11/2025 - 03:35 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001777231
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	FLUOR CORP
SEC File Number	001-16129
Address of Issuer	6700 LAS COLINAS BLVD IRVING TEXAS 75039
Phone	4693987000
Name of Person for Whose Account the Securities are To Be Sold	Fields Mark E
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
COMMON	MERRILL LYNCH 13355 NOEL ROAD SUITE 700 DALLAS TX 75240	55178	3440858.00	161664371	08/11/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
COMMON	02/23/2016	RESTRICTED STOCK	FLUOR CORPORATION			5178	02/23/2016	EQUITY AWARD
COMMON	11/11/2022	RESTRICTED STOCK	FLUOR CORPORATION			46785	11/11/2022	EQUITY AWARD

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	08/11/2025
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	08/22/2024
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	MARK FIELDS
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)